134 related articles for article (PubMed ID: 37335445)
1. Differences in Transcriptomic Profiles of Brain and Thyroid Tumors with NTRK Gene Rearrangement.
Kechin AA; Koryukov MA; Smertina MA; Borobova VS; Oscorbin IP; Ivanov AA; Bakharev SY; Boyarskikh UA; Kushlinskii NE; Filipenko ML
Bull Exp Biol Med; 2023 May; 175(1):78-85. PubMed ID: 37335445
[TBL] [Abstract][Full Text] [Related]
2. Prediction of EVT6-NTRK3-Dependent Papillary Thyroid Cancer Using Minor Expression Profile.
Kechin AA; Ivanov AA; Kel AE; Kalmykov AS; Oskorbin IP; Boyarskikh UA; Kharpov EA; Bakharev SY; Oskina NA; Samuilenkova OV; Vikhlyanov IV; Kushlinskii NE; Filipenko ML
Bull Exp Biol Med; 2022 Jun; 173(2):252-256. PubMed ID: 35737155
[TBL] [Abstract][Full Text] [Related]
3. Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology.
Abi-Raad R; Prasad ML; Adeniran AJ; Cai G
Cancer Cytopathol; 2020 Nov; 128(11):803-811. PubMed ID: 32931153
[TBL] [Abstract][Full Text] [Related]
4. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.
Li XJ; Wen R; Wen DY; Lin P; Pan DH; Zhang LJ; He Y; Shi L; Qin YY; Lai YH; Lai JN; Yang JL; Lai QQ; Wang J; Ma J; Yang H; Pang YY
Mol Med Rep; 2020 Sep; 22(3):2199-2218. PubMed ID: 32705210
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
[No Abstract] [Full Text] [Related]
9. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
10. MiR-375: A prospective regulator in medullary thyroid cancer based on microarray data and bioinformatics analyses.
Shi L; Zhao SM; Luo Y; Zhang AW; Wei LH; Xie ZY; Li YY; Ma W
Pathol Res Pract; 2017 Nov; 213(11):1344-1354. PubMed ID: 29033189
[TBL] [Abstract][Full Text] [Related]
11. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of the long non-coding RNA 01296/microRNA-143-3p/MSI2 axis in development of thyroid cancer.
Wang ZL; Wang C; Liu W; Ai ZL
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31693087
[TBL] [Abstract][Full Text] [Related]
13. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
14. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of LncRNA HOTAIR is Associated with Poor Prognosis in Thyroid Carcinoma: A Study Based on TCGA and GEO Data.
Li HM; Yang H; Wen DY; Luo YH; Liang CY; Pan DH; Ma W; Chen G; He Y; Chen JQ
Horm Metab Res; 2017 May; 49(5):388-399. PubMed ID: 28351094
[TBL] [Abstract][Full Text] [Related]
18. Analysis of
Okamura R; Boichard A; Kato S; Sicklick JK; Bazhenova L; Kurzrock R
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30637364
[TBL] [Abstract][Full Text] [Related]
19. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
20. [Study of
Zhang HD; Yin XN; Cai ZL; Zhang B
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):769-774. PubMed ID: 34530557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
